8-K: ORIC Pharmaceuticals Presents Promising Clinical Data and Outlines Path to Pivotal Studies at J.P. Morgan Healthcare Conference

ORIC Pharmaceuticals highlighted its progress with ORIC-114 and ORIC-944, aiming for pivotal studies in 2025 and 2026, respectively, while also showcasing a strong financial position.

Summary

• ORIC Pharmaceuticals presented an updated corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.
• The company is focused on developing therapies to overcome resistance in cancer, with two lead programs, ORIC-114 and ORIC-944, advancing towards pivotal studies.
• ORIC-114, a potential best-in-class TKI, targets NSCLC with EGFR exon 20, HER2 exon 20, and EGFR atypical mutations.
• ORIC-944, a potential best-in-class PRC2 inhibitor, targets mCRPC.
• The company has a dual engine for pipeline expansion, aiming for one new IND candidate every 18 months.
• ORIC has a strong financial position with $282 million in cash and investments, expected to fund operations into late 2026.
• Anticipated data milestones include ORIC-114 data in 1H25 for 2L EGFR exon 20 and 2L+ HER2 exon 20, 2H25 for 2L+ EGFR atypical, and 1H26 for 1L EGFR exon 20.
• Mid-2026 data is expected for ORIC-114 in 1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical.
• ORIC-944 combination data with AR inhibitors is expected in 4Q25 / 1H26.
• ORIC-114 has shown promising clinical activity, including a complete CNS response in a patient with EGFR exon 20 mutated NSCLC and active brain metastases.
• ORIC-944 has demonstrated robust target engagement and a favorable safety profile in early clinical trials.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data, a strong financial position, and clear plans for future development. The company's focus on addressing unmet needs in cancer treatment and its strategic collaborations contribute to a favorable sentiment.

Positives

• ORIC-114 has shown a complete CNS response in a patient with EGFR exon 20 mutated NSCLC and active brain metastases, a significant achievement.
• ORIC-114 has demonstrated superior brain penetration compared to other exon 20 targeted agents, addressing a key limitation of existing therapies.
• ORIC-944 has a clinical half-life of ~20 hours and no signs of CYP autoinduction, supporting once-daily dosing and consistent drug exposure.
• ORIC-944 has shown synergistic activity with AR inhibitors in preclinical models, providing a strong rationale for combination therapy.
• The company has a strong cash position of $282 million, providing a runway into late 2026.
• ORIC-114 has shown tumor regressions across multiple active doses in EGFR and HER2 exon 20 NSCLC patients.
• ORIC-944 has shown a 75% reduction in H3K27me3 in monocytes, indicating strong target engagement.
• ORIC-944 plus apalutamide has shown confirmed PSA50 response in 3 patients and PSA90 response in 2 patients in initial cohorts.

Negatives

• The document contains forward-looking statements that are subject to risks and uncertainties, including the potential for clinical trial results to differ from expectations.
• The company is still in the early clinical stage, and there is no guarantee that the product candidates will be approved for marketing.
• The company is dependent on third-party contract research organizations, suppliers, and manufacturers, which could impact the development and commercialization of its product candidates.
• The document mentions that the company has incurred losses since its inception and expects to continue to incur losses for the foreseeable future.

Risks

• The timing of the initiation, progress, and results of preclinical studies and clinical trials are subject to risks and uncertainties.
• There are risks associated with discovering, developing, and commercializing drugs that are safe and effective for use in humans.
• Health emergencies, economic instability, or international conflicts could negatively impact operations, including clinical trials.
• Clinical trials of product candidates may differ from preclinical, initial, interim, preliminary, or expected results.
• The company's ability to obtain regulatory filings and approvals is not guaranteed.
• There are risks associated with the commercialization of product candidates, if approved.
• The company's ability to manufacture and supply product candidates for clinical trials and commercial use is subject to risks.
• The company's estimates regarding expenses, future revenue, capital requirements, and needs for financing are subject to risks.
• The company's ability to retain key personnel and hire additional qualified professionals is subject to risks.
• The company's ability to contract with third-party organizations and their ability to perform adequately is subject to risks.
• The pricing, coverage, and reimbursement of product candidates, if approved, are subject to risks.
• Developments relating to competitors and the industry, including competing product candidates and therapies, are subject to risks.
• Regulatory developments in the United States and foreign countries are subject to risks.
• General economic and market conditions are subject to risks.

Future Outlook

ORIC Pharmaceuticals anticipates multiple potential NDA filings in 2027 and 2028 for ORIC-114, and expects to initiate pivotal studies for both ORIC-114 and ORIC-944 in the near future. The company also plans to continue expanding its pipeline with a goal of one new IND candidate every 18 months.

Management Comments

• The company is dedicated to overcoming resistance in cancer.
• ORIC is targeting one new IND candidate every 18 months.
• The company has a heritage of discovering, developing, and commercializing oncology therapies.
• Two potential best-in-class programs are expected to enter pivotal studies in 2H25 (ORIC-114) and early 2026 (ORIC-944).

Industry Context

ORIC's focus on overcoming resistance in cancer aligns with a significant trend in oncology drug development. The company's approach to targeting specific mutations and pathways, such as EGFR, HER2, and PRC2, reflects a growing emphasis on precision medicine. The collaborations with Johnson & Johnson and Bayer highlight the industry's interest in combination therapies to improve patient outcomes.

Comparison to Industry Standards

• ORIC-114's ability to achieve a complete CNS response in a patient with EGFR exon 20 mutated NSCLC and active brain metastases is a significant differentiator compared to other EGFR exon 20 inhibitors like amivantamab, CLN-081, sunvozertinib, furmonertinib, and BLU-451, which typically exclude patients with prior EGFR exon 20 treatment or untreated CNS metastases.
• ORIC-114 has demonstrated superior brain penetration compared to other exon 20 targeted agents, addressing a key limitation of existing therapies like mobocertinib, where ~35% of patients had CNS metastases at baseline and experienced worse outcomes.
• ORIC-944's clinical half-life of ~20 hours and lack of CYP autoinduction are superior to first-generation PRC2 inhibitors like tazemetostat and mevrometostat, which have shorter half-lives and/or CYP autoinduction issues.
• ORIC-944's synergistic activity with AR inhibitors in preclinical models is consistent with the industry's trend towards combination therapies, as validated by Pfizer's mevrometostat data in prostate cancer.
• ORIC-944's single agent activity in preclinical prostate cancer models appears superior to data reported by Epizyme with tazemetostat in an enzalutamide-resistant in vivo prostate cancer model.

Stakeholder Impact

• Shareholders may benefit from the potential for successful drug development and commercialization.
• Employees may benefit from the company's growth and success.
• Patients may benefit from the development of new and effective cancer therapies.
• The company's collaborations with Johnson & Johnson and Bayer may benefit these partners through potential commercial opportunities.

Next Steps

• ORIC-114 is expected to initiate multiple accelerated registrational cohorts in 2H 2025.
• ORIC-114 is expected to initiate potential 1L registrational trials in 2026.
• ORIC-944 combination data with AR inhibitors is expected in 4Q25 / 1H26.
• The company plans to continue expanding its pipeline with a goal of one new IND candidate every 18 months.

Key Dates

Keywords

ORIC-114, ORIC-944, NSCLC, mCRPC, EGFR, HER2, PRC2, TKI, Clinical Trials, Oncology, Cancer Therapy, Drug Development, Pharmaceuticals, Brain Metastases, AR Inhibitors